News
A new vaccine designed to combat cancer cells in patients with colorectal and pancreatic cancer showed promising results in ...
Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...
Bayer has inked a global licensing deal with Kumquat Biosciences for a KRAS G12D cancer drug, allowing Phase 1a trials to be ...
A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...
New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.
18h
News-Medical.Net on MSNNovel vaccine shows promise against KRAS-driven pancreatic and colorectal cancers
A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown ...
Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...
A new pancreatic cancer vaccine has appeared to slow disease progression and increase survival for patients in an early trial ...
The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...
Bayer & Kumquat Biosciences enter global license and collaboration to develop and commercialize Kumquat’s KRAS G12D inhibitor: Berlin, Germany Wednesday, August 13, 2025, 11:00 ...
In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back ...
4d
Medpage Today on MSNKRAS Inhibitor Reduces Progression Risk in Pretreated Lung Cancer
The objective response rate (ORR) was 32% with adagrasib versus 9% with docetaxel (OR 4.68, 95% CI 2.56-8.56, P <0.0001), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results